Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
暂无分享,去创建一个
C. Barbas | Q. Sattentau | J. Moore | D. Ho | J. Robinson | John P. Moore | Y. Cao | L. Qing | J. Pyati | R. Koduri | D. Burton | Yun-zhen Cao | HO DAVIDD. | Y. Cao | Limo Qing
[1] M. Robert-Guroff,et al. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.
[2] Robin A. Weiss,et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.
[3] M. Hirsch,et al. Antibody to lymphadenopathy-associated virus in AIDS. , 1985, The New England journal of medicine.
[4] J. Coffin. Genetic variation in AIDS viruses , 1986, Cell.
[5] R. Gallo,et al. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[6] A J Langlois,et al. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. , 1986, Science.
[7] L. Arthur,et al. Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[8] C. Boucher,et al. Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. , 1988, AIDS.
[9] H. Mitsuya,et al. Designing CD4 immunoadhesins for AIDS therapy , 1989, Nature.
[10] J. Moore,et al. An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. , 1989, AIDS.
[11] D. Bolognesi. Prospects for prevention of and early intervention against HIV. , 1989, JAMA.
[12] A J Langlois,et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[13] A. Profy,et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.
[14] W. O'brien,et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain , 1990, Nature.
[15] J. Robinson,et al. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Moore,et al. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. , 1990, AIDS.
[17] J. Robinson,et al. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. , 1990, AIDS research and human retroviruses.
[18] M. Champe,et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160 , 1990, Nature.
[19] D. Ho,et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Spouge,et al. HIV requires multiple gp120 molecules for CD4-mediated infection , 1990, Nature.
[21] D. Ho,et al. Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[22] D. Ho,et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.
[23] K. Steimer,et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.
[24] S. Zolla-Pazner,et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[25] I. Chen,et al. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Kieny,et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[27] Q. Sattentau,et al. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4 , 1991, Journal of virology.
[28] J. Moore,et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.
[29] P. Earl,et al. Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers , 1992, Journal of Virology.
[30] J. Sodroski,et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.
[31] D. Ho,et al. Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4 , 1992, Journal of virology.
[32] H. Robinson,et al. Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Schooley,et al. Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] S. Zolla-Pazner,et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.
[35] W. Morrow,et al. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site. , 1992, Journal of immunology.
[36] J. Mcdougal,et al. Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus type 1 (HIV-1) infectivity and their relation to primary HIV-1 isolates with reduced sensitivity to sCD4 , 1993, Journal of virology.
[37] G. Nakamura,et al. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1 , 1993, Journal of virology.
[38] J. Moore,et al. The HIV gp120-CD4 interaction: A target for pharmacological or immunological intervention? , 1993 .
[39] B. Haynes,et al. Scientific and social issues of human immunodeficiency virus vaccine development. , 1993, Science.
[40] HIV tropism , 1993, Nature.
[41] M. Reitz,et al. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. , 1993, The Journal of biological chemistry.
[42] J. Moore,et al. Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. , 1993, AIDS research and human retroviruses.
[43] HIV vaccine trials: some design issues including sample size calculation. , 1993, Journal of acquired immune deficiency syndromes.
[44] D. Ho,et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. , 1993, Science.
[45] J. Moore,et al. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.
[46] M. Merson,et al. Slowing the spread of HIV: agenda for the 1990s. , 1993, Science.
[47] Jitters jeopardize AIDS vaccine trials. , 1993, Science.
[48] R. Willey,et al. Amino acid substitutions in the human immunodeficiency virus type 1 gp120 V3 loop that change viral tropism also alter physical and functional properties of the virion envelope , 1994, Journal of virology.
[49] B. Chesebro,et al. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.
[50] F. Hufert,et al. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum , 1994, Journal of virology.
[51] S. Zolla-Pazner,et al. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. , 1994, Journal of immunology.
[52] T. Matthews. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. , 1994, AIDS research and human retroviruses.
[53] J. Sodroski,et al. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 , 1994, Journal of virology.
[54] R. Belshe,et al. Comparison of the immune response to recombinant gp120 in humans and chimpanzees , 1994, AIDS.
[55] J. Sodroski,et al. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies , 1994, Journal of virology.
[56] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[57] E. Emini,et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Mascola,et al. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. , 1994, The Journal of infectious diseases.
[59] C. Kuiken,et al. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. , 1994, Virology.
[60] D. Ho,et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.
[61] J. Moore,et al. Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.
[62] D R Burton,et al. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[63] E. Malvoisin,et al. Analysis of the human immunodeficiency virus type 1 envelope protein interaction with the CD4 host cell receptor. , 1994, The Journal of general virology.
[64] L. Sawyer,et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated , 1994, Journal of virology.
[65] The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. , 1994, The Journal of infectious diseases.
[66] P. Berman,et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.
[67] M. Bendinelli,et al. Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system , 1994, Journal of virology.
[68] J. Moore,et al. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures , 1994, Journal of virology.
[69] J. Moore,et al. Studies with monoclonal antibodies to the V3 region of HIV-1 gp120 reveal limitations to the utility of solid-phase peptide binding assays. , 1994, Journal of acquired immune deficiency syndromes.
[70] S. Zolla-Pazner,et al. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D , 1994, Journal of virology.
[71] M. Martin,et al. Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1 , 1994, Journal of virology.
[72] P. Earl,et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities , 1994, Journal of virology.
[73] A. Trkola,et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B , 1995, Journal of virology.